Modification of metabolic syndrome parameters following the administration of polyglucosamine L112: results of a subgroup analysis of subjects enrolled in a double blind randomised placebo controlled clinical investigation.

ABSTRACT:

Background

Up to now, scientific literature has not reported studies evaluating the efficacy of polyglucosamine L112 on body weight, insulin resistance, and cholesterol levels in patients with metabolic syndrome, despite its known antioxidant properties and potential to reduce these parameters, making it a promising candidate for treating metabolic syndrome.

Objective

The aim of this study was to examine the activity of L112 in a subgroup of cases suffering from metabolic syndrome (MS).

Methods

A subgroup of 26 subjects (8 males and 18 females; age 55 ± 11.3 years; BMI 31.1 ± 1.35 kg/m²) was selected from a previous larger RCT study and statistically analyzed. Among them, 12 subjects were administered a diet and placebo, while 14 were administered a diet and L112 at a

SUBMITTER: Rondanelli M 

PROVIDER: S-EPMC12403585 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature